APC members Stuart Johnson and his wife Brandi, of Aiken, SC, didn’t know their US Senator Tim Scott, but they signed up to meet with his staffer last September during Compounders on Capitol Hill. read more →
In recent weeks there’s been a persistent rumor that the governing body for horse-racing has banned compounded drugs because they are not FDA approved. But that’s not the case. read more →
Later this spring, we’ll be debuting a new 15-hour certificate program, “The Ethical, Legal, and Regulatory Framework of Pharmacy Compounding.” read more →
The California Board of Pharmacy’s Enforcement and Compounding Committee met yesterday to discuss proposed regulations related to sterile compounding. read more →
In advance of the April 1, 2023, enforcement date for the new animal compounding guidance from FDA, APC and PCCA are partnering to offer a CE webinar aimed at helping you bring your animal compounding operations into compliance. read more →
In response to a request from APC and NCPA, FDA’s Center for Veterinary Medicine last week issued a Letter to Industry explaining the phased-in approach to enforcement the agency plans to take on GFI 256. read more →
The APC Fellows Program recognizes the distinguished contributions our compounding pharmacist and pharmacy technician members have made to the profession and to their respective communities.
All applicants must be registered pharmacists or pharmacy technicians who have practiced pharmacy for at least five years and practiced in the compounding pharmacy profession for at least three years.
The deadline for 2023 nominations has been extended to June 1, which provides plenty of time for you to learn more about eligibility requirements and submit your application. Get started on our APC Fellows web page.
In advance of the April 1, 2023, enforcement date for the new animal compounding guidance from FDA, APC and PCCA are partnering to offer a CE webinar aimed at helping you bring your animal compounding operations into compliance–and to make sure the veterinarians you work with understand the changes required by GFI 256.
$25 per person (All registration fees donated to APC)
CE = 1 hour
All compounding pharmacists, technicians and other compounding team members are invited to join PCCA Vice President of Clinical Services A.J. Day, PharmD, and PCCA Director of Clinical Services Matt Martin, PharmD, BCSCP, to learn what’s new in GFI 256 and what you need to know now.
Learning objectives:
Describe the legal framework that GFI 256 discusses for animal drugs.
Identify the parameters for compounding patient specific animal medications in GFI 256.
Illustrate how to differentiate a compounded animal medication from a copy of a manufactured drug product.
Analyze situations when compounding from a manufactured drug product can produce an unacceptable final compounded preparation.
Review the criteria for compounding for office stock and how drugs can become eligible for FDA’s list related to this.
Purchase includes:
CE = 1 hour (Must be claimed within 14 days of the live event.)
Recording available to paid registrants for 3 months post-live event.
With enforcement of FDA’s GFI 256 set to commence April 1, APC has developed a new Prescriber Brief to help you coach the veterinarians you work with on what they must document on prescriptions for compounded animal drugs.
It joins a suite of members-only Prescriber Briefs that include topics such as the regulatory framework of pharmacy compounding, compounding peptides, and the “Wet Signature” Act.
PS: You’ll need your a4pc.org member login to access these.
For too long, the story of compounding has been told in the media by people with a vested interest in marginalizing our industry. They would decide your future.
But we are doing something about it.
Compounding the Joy of Living: The campaign for pharmacy compounding, is us taking back control of our own story. It’s us taking back control of our own destiny.
Above is an example of the kinds of ads we are working on.
This phase of the campaign is the third year of our original 3-year initiative. We are expanding our message beyond compounded hormones, and we need your help. We need your financial support.
Because the simple truth is that we cannot impact our world without money.
We have a choice. To sit on the sidelines and let others determine our fate. Or get into the fight and tell our own story.
You transform the lives of your patients every day. The world needs to know that.
Bummed that you missed our annual State of Compounding Law Changes live webinar in January?
Wish you could finish up watching this year’s EduCon programming?*
No worries. APC has an extensive library of on-demand webinars available—including EduCon 2023—for you to access whenever and wherever.
*It’s not too late to still get credit if you registered for the live presentation of EduCon. You can also be a new registrant for the on-demand programs. All are available until April 30, 2023. Pharmacists and pharmacy technicians who view the on-demand CPE activities will be awarded home-study CPE credit.
Over the past two years, The Townsend Letter has partnered with APC to alert prescribers and others about the threat to restrict compounded hormone therapy. Now, the folks at The Townsend Letter want to make sure you know you can get a free subscription to their weekly e-newsletter.
Founded by Jonathan Collin, MD, The Townsend Letter serves as a forum for integrative and naturopathic practitioners. It’s a free subscription available by request from subscription@townsendletter.com.
Dr. Collin invites compounding pharmacies to subscribe, and also to submit articles, invitations for webinars and meetings, etc. Recent issues are always posted at http://www.townsendletter.com.
Proposed DEA rules would provide safeguards for telemedicine consultations by a medical practitioner who has never conducted an in-person evaluation of a patient that result in the prescribing of a controlled medication for that patient. This would affect prescriptions for compounded testosterone, for instance.
However, the proposed telemedicine rules would allow medical practitioners to prescribe 30-day supplies of both Schedule III-V non-narcotic controlled medications and buprenorphine for the treatment of opioid use disorder.
Access the full proposals here and here. The public has 30 days from February 24 to review and comment on the proposals, which DEA will then consider before drafting final regulations.
For compounding pharmacy and facility owners, Owner Summit is the top learning, planning and idea-sharing event of the year—and it’s less than one month away!
And here’s some good news: We’ve managed to buy you a few extra days to take advantage of our reduced hotel room rate for the conference. The new cutoff for special rates at Marriott’s Grand Hotel is NOW Tuesday, March 7.
Please note the APC room block has very limited availability remaining for March 26 – 28. However, the APC room block for Friday, March 24 and Saturday, March 25 is currently sold out.
This year’s fast-paced Owner Summit program is guaranteed to wake you up from the doldrums with sessions on growing your pharmacy team, incorporating new ideas, and increasing operational efficiency. We guarantee you’ll take home new ideas you can implement immediately.
Earlier this week, APC sent an updated briefing memo to all 50 state boards of pharmacy regarding GFI #256 and CVM’s recent responses to our questions regarding compliance.
Our communication went to the BOP director, not to the board members. We encourage you to share the CVM replies with your board of pharmacy members, to ensure they see it and can help guide state enforcement of the GFI that syncs with FDA’s approach and is reasonably uniform across states.
APC’s annual Owner Summit—March 26-28 at the Grand Hotel, Point Clear, Alabama—is THE conference that is 100 percent designed just for owners like you.
Owner Summit packs two intense days with practical, actionable presentations from experts that cover issues critical to pharmacy compounding in 2023: Online payments, software solutions, sales-team management, preventing medication errors, and much, much more.
You’re making a smart business investment—one that will begin delivering an ROI as soon as you’re back at work. Registration is $999 for PFMs and $1299 for all others.
With enforcement of FDA’s GFI 256 set to commence April 1, APC has developed 
